Update of the CAVEI recommendation on the use of COVID-vaccines 19 in pregnant women - 27 April 2021

CAVEI recommends to:

1. Postpone the COVID-19 vaccination campaign for pregnant women until there is more evidence on the safety and efficacy of COVID-19 vaccines in this group and that comes from clinical studies of vaccines authorized for use in Chile.
2. In pregnant women at high risk of exposure to SARS-CoV-2 infection, for example, a health worker, or who suffer from chronic diseases that increase their risk of severe COVID-19, vaccination could be considered starting from second trimester of gestation with COVID-19 vaccine based on messenger RNA from Pfizer / BioNTech or with the inactivated vaccine from Sinovac Biotech, after evaluation risk-benefit plan with your caregiver, doctor or midwife / midwife, who must inform, in any case, on the scarce information on safety and efficacy of vaccines COVID-19 in pregnant women. The two-dose vaccination schedule must be completed with the same vaccine, that is, two doses of Pfizer vaccine or two doses of vaccine CoronaVac, with separation of 28 days between doses of COVID-19 vaccines and 14 days with other vaccines.
3. Carry out vaccination surveillance in pregnant women, both inadvertent vaccination and those that receive it with informed consent.
4. Maintain in the general population, and in pregnant women in particular, the measures of infection prevention and control of SARS-CoV-2 in force in the country: use of mask, hand washing, physical distancing, teleworking, quarantines and others measures adopted within the framework of the Step by Step plan of the Government of Chile.